Royal Bank of Canada
BHVN

Royal Bank of Canada’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Royal Bank of Canada’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,758
Closed -$2.08M – 8250
2022
Q3 		$2.08M Sell
13,758
-11,539
-46% -$1.71M ﹤0.01% 2826
2022
Q2 		$3.69M Sell
25,297
-14,934
-37% -$1.91M ﹤0.01% 2353
2022
Q1 		$4.77M Sell
40,231
-1,068
-3% -$133K ﹤0.01% 2300
2021
Q4 		$5.69M Buy
41,299
+24,666
+148% +$3.14M ﹤0.01% 2289
2021
Q3 		$2.31M Sell
16,633
-10,841
-39% -$1.35M ﹤0.01% 2963
2021
Q2 		$2.67M Sell
27,474
-5,866
-18% -$476K ﹤0.01% 2811
2021
Q1 		$2.28M Sell
33,340
-6,153
-16% -$498K ﹤0.01% 2897
2020
Q4 		$3.38M Buy
39,493
+21,671
+122% +$1.84M ﹤0.01% 2474
2020
Q3 		$1.16M Sell
17,822
-2,549
-13% -$167K ﹤0.01% 3143
2020
Q2 		$1.49M Buy
20,371
+18,786
+1,185% +$1,000K ﹤0.01% 2854
2020
Q1 		$54K Sell
1,585
-8,364
-84% -$382K ﹤0.01% 5120
2019
Q4 		$542K Buy
9,949
+8,483
+579% +$420K ﹤0.01% 3924
2019
Q3 		$62K Sell
1,466
-3,377
-70% -$143K ﹤0.01% 5036
2019
Q2 		$212K Buy
4,843
+4,488
+1,264% +$253K ﹤0.01% 4452
2019
Q1 		$18K Buy
355
+42
+13% +$1.81K ﹤0.01% 5713
2018
Q4 		$12K Sell
313
-595
-66% -$21.5K ﹤0.01% 5828
2018
Q3 		$33K Buy
908
+631
+228% +$23.2K ﹤0.01% 5440
2018
Q2 		$10K Buy
277
+129
+87% +$4.09K ﹤0.01% 5843
2018
Q1 		$4K Buy
148
+72
+95% +$2.15K ﹤0.01% 6026
2017
Q4 		$2K Sell
76
-849
-92% -$23.4K ﹤0.01% 6349
2017
Q3 		$34K Buy
+925
New +$28.1K ﹤0.01% 5659

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Royal Bank of Canada's BHVN Position: Q4 2022 in Review

Royal Bank of Canada sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 13,758 shares — an estimated $2.08M sold.

Royal Bank of Canada first reported a position in BHVN in Q3 2017 and held it in 21 quarters. The position peaked at $5.69M in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Royal Bank of Canada reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Royal Bank of Canada sold 13,758 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $2.08M.
  • Royal Bank of Canada first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2017 and held it in 21 quarters.
  • Royal Bank of Canada's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $5.69M in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Royal Bank of Canada's 13F filing for Q4 2022, filed 14 Feb 2023.